A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01546623
First received: February 28, 2012
Last updated: October 14, 2014
Last verified: October 2014

February 28, 2012
October 14, 2014
March 2012
April 2014   (final data collection date for primary outcome measure)
The rate of suppression of serum testosterone to castrate level [ Time Frame: From the start of study drug administration through Week 48 ] [ Designated as safety issue: No ]
Comparison of the proportion of patients maintained at castration level
Same as current
Complete list of historical versions of study NCT01546623 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
A Phase 3, Multi-center, Randomized, Open-label, Parallel-group, Comparative Study of TAP-144-SR (3M) to Evaluate Hormone Dynamics, Pharmacokinetics, Safety and Efficacy of TAP-144-SR (6M) 22.5 mg Subcutaneous Injection for 48 Weeks in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) will be evaluated against TAP-144-SR(3M) in prostate cancer patients previously treated with hormonal therapy.

Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostate Cancer
  • Drug: TAP-144-SR(6M)
  • Drug: TAP-144-SR(3M)
  • Experimental: TAP-144-SR(6M)
    TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.
    Intervention: Drug: TAP-144-SR(6M)
  • Active Comparator: TAP-144-SR(3M)
    TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.
    Intervention: Drug: TAP-144-SR(3M)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
160
April 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The participant has histopathologically confirmed prostate cancer in Japanese.
  2. The participant has prostate cancer in the clinical stages of T1b-T4, N-any and M-any by TNM classification on clinical diagnosis at the time of diagnosis.
  3. The participant has ECOG performance status of grades 0, 1, or 2 at screening.
  4. The participant with PSA level which has not increased 25 % or greater and 2 ng/mL or more from the nadir at the measurement points 4 weeks or longer apart within the screening period of 12 weeks.
  5. Patients who receive the marketed product for 3 months (LEUPLIN SR FOR INJECTION KIT 11.25) at screening
  6. Patients who have received the marketed products, TAP-144-SR (1M) and TAP-144-SR (3M), for 24-96 weeks in total at the scheduled starting date of the study drug, but not including administration period treated as neoadjuvant therapy for prostatectomy and/or radiation therapy
  7. Patients who have continued the nonsteroidal antiandrogen for longer than 12 weeks at the scheduled starting date of the study drug, if a nonsteroidal antiandrogen is concomitantly administered
  8. The participant with a serum testosterone level at screening < 100ng/dL
  9. The participant meets the following criteria of renal, bone-marrow and hepatic functions on the laboratory test results at screening:

(1) Renal function: serum creatinine level< 1.5 times the upper limit of normal (ULN) (2) Bone-marrow function: white blood count ≥ 3,500/ mm3, platelet count ≥ 100,000/L, hemoglobin ≥ 10.0g/dL (3) Hepatic function: AST(GOT), ALT(GPT), ALP and total bilirubin ≤ 2.5 times the ULN 10. The participant's life expectancy is at least 24 months at informed consent.

Exclusion Criteria:

  1. The participant has active multiple primary cancers, (synchronous multiple primary cancer or metachronous multiple primary cancer with the disease-free survival ≤ 5 years)
  2. The participant has received surgical castration.
  3. The participant has ever received LHRH agonists other than commercially available 1-month or 3-month depot of leuprolide acetate.
  4. The participant has ever received LHRH antagonists.
  5. Patients who have previously received estrogen preparations or corticosteroids for prostate cancer
  6. Patients who have previously received chemotherapy for prostate cancer
  7. Patients who are receiving or received the marketed product for 3 months (LEUPLIN SR FOR INJECTION KIT 11.25) or the marketed products for 1 month (LEUPLIN FOR INJECTION 3.75 and KIT 3.75) as an adjuvant therapy after prostatectomy and/or radiotherapy
  8. Patients who are receiving or received the marketed product for 3 months (LEUPLIN SR FOR INJECTION KIT 11.25) for intermittent androgen deprivation therapy
  9. Patients who received the following drugs within 24 weeks (168 days) after starting the study drug: Steroidal antiandrogens, type II 5α-reductase inhibitors
  10. The participant received any of the following within 16 weeks (112 days) prior to study enrollment:

(1) Radiotherapy. As for I-125 brachytherapy, within 35 weeks (245 days) prior to study enrollment.

(2) Prostatectomy (3) Experimental therapy including high-intensity focused ultrasound therapy (HIFU), immunotherapy, and gene therapy 11. Patients who received the following drugs within 4 weeks (28 days) before starting the study drug: Testosterones, ketoconazole(except for external preparations), spironolactone, corticosteroids (excluding their inhalants and external preparations), and Chinese medicines and dietary supplements containing saw palmetto 12. Patients whose QTcF interval exceeded 460 msec on the 12-lead electrocardiogram at screening 13. The participant has a history of hypersensitivity to synthetic LHRH, LHRH derivative or any component of the study drug.

14. The participant has central nervous system metastasis which requires treatment or which is symptomatic.

15. The participant already has a history or has a complication or may have renal disorder caused by spinal cord compression or ureteric obstruction.

16. The participant has a history of serious drug allergic reaction/hypersensitivity 17. The participant has a history of, or has been diagnosed with thromboembolism including myocardial infarction, cerebral infarction, venous thrombosis, and pulmonary embolism, or cardiac failure

Male
20 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT01546623
TAP-144-SR(6M)IP/CPH-002, U1111-1128-6861, JapicCTI-121763
No
Takeda
Takeda
Not Provided
Not Provided
Takeda
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP